PD-1 inhibitor treatment outcomes for cutaneous squamous cell carcinoma in patients over 85: a comparative analysis

Key Points

• To evaluate PD-1 inhibitor treatment outcomes in patients with cutaneous squamous cell carcinoma over 85 years old.
• Comparative analysis of treatment outcomes for PD-1 inhibitors in elderly patients.
• Assessment of progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS).
• Comparison across different age groups.
• Cemiplimab shows comparable efficacy and tolerability across age groups.
• No significant difference in PFS and CSS.
• Shorter OS in very elderly patients attributed to non-cancer mortality rather than reduced treatment efficacy.